From Your Cells to the Lab — How Personalized Disease Models Work

One of the most powerful tools in modern rare disease research is something that would have sounded like science fiction just twenty years ago: taking a patient's own cells and transforming them into a living, testable model of their disease in the laboratory.

This technology — known as induced pluripotent stem cell (iPSC) reprogramming — has fundamentally changed what's possible for rare disease families. It means that even for conditions so rare that only a handful of people in the world are affected, scientists can now build a personalized research platform and begin testing potential treatments. No large patient cohorts required. No waiting for someone else to study your disease. Your cells become the starting point.

The Science Behind iPSCs

In 2006, Japanese scientist Shinya Yamanaka made a discovery that would earn him the Nobel Prize in Physiology or Medicine: by introducing just four specific genes into ordinary adult cells, he could reprogram them back to a pluripotent state — meaning they regained the ability to become virtually any cell type in the human body.

This was a breakthrough of enormous significance. Previously, the only way to obtain pluripotent cells was from embryonic sources, which carried both ethical concerns and practical limitations. Yamanaka's method meant that a simple blood draw or skin biopsy from any patient could provide the raw material for creating stem cells — and from those stem cells, researchers could generate the specific cell types affected by a patient's disease.

For rare disease research, this opened a door that had been closed for decades. Suddenly, it was possible to study a patient's disease at the cellular level, in the laboratory, using their own genetic material.

How RareLabs Uses This Technology

When a family comes to RareLabs, the process begins with something remarkably simple: a small blood sample or skin biopsy. This sample is collected by your local physician — there's no need to travel to a specialized center.

From that sample, our laboratory team begins the reprogramming process. Here's what happens, step by step:

Step 1: Cell Collection and Reprogramming. Your blood or skin cells are treated with reprogramming factors that convert them into iPSCs. This process takes several weeks, but the result is a renewable source of stem cells that carry your exact genetic makeup — including the mutation responsible for your disease.

Step 2: Differentiation into Disease-Relevant Cells. Once we have iPSCs, we can direct them to become the specific type of cell affected by the disease. If the condition affects the brain, we create neurons. If it affects the heart, we create cardiomyocytes. If it affects muscle tissue, we create myocytes. The result is a population of cells that behave the way your disease behaves — in a dish, where we can observe and test them.

Step 3: Creating a "Corrected" Control Line. Using CRISPR gene editing, we also create an isogenic control — a version of your cells where the disease-causing mutation has been corrected. This gives us a direct comparison: disease cells versus healthy cells, with the same genetic background. Any differences we observe can be attributed to the mutation itself, not to other genetic variation.

Step 4: Quality Control and Preservation. Every cell line undergoes rigorous quality checks. We verify genetic stability, confirm that the cells have been properly reprogrammed, and ensure they reliably model the disease phenotype. Once validated, all cell lines are frozen and preserved in our biobank, available for current and future testing.

Step 5: Developing the Assay — Your Disease's "Test." Within approximately four weeks of receiving your sample, our scientists develop a customized assay — a specific, measurable test that captures how your disease manifests at the cellular level. This might involve measuring how cells function, examining their structure under high-powered microscopy, or tracking changes in gene expression. The assay becomes the foundation for all treatment screening that follows.

Why Personalization Matters

In traditional drug development, researchers typically work with generic cell lines or animal models that approximate a disease but don't capture the specific genetic nuances of any individual patient. For common diseases, this approach can work reasonably well because the patient population is large enough to account for genetic variation in clinical trials.

For rare diseases — especially ultra-rare conditions where each patient may carry a unique mutation — this one-size-fits-all approach falls short. A drug that works for one mutation may not work for another, even within the same gene. Personalized disease models solve this problem by creating a testing platform that is specific to your family member's exact genetic condition.

This is not theoretical. iPSC-based disease modeling has been successfully used to study hundreds of rare conditions, identify drug candidates, and in some cases, guide treatment decisions for individual patients. The technology is mature, validated, and increasingly accessible.

Your Cells, Your Answers

The beauty of this approach is that it puts the patient's biology at the center of the research. We're not guessing about how your disease works based on animal models or cell lines from unrelated patients. We're studying your disease, in your cells, with your mutation.

And because all cell lines are preserved, they remain available indefinitely. If new treatment approaches emerge in the future — new drugs, new gene therapies, new technologies we haven't yet imagined — your cells will be ready to test them.

Your cells become the foundation for the search for answers. And that search can begin today.